Takeda Pharmaceutical Gestione

Gestione criteri di controllo 2/4

Takeda Pharmaceutical Il CEO è Christophe Weber, nominato in Jun2014, e ha un mandato di 10.42 anni. la retribuzione annua totale è ¥ 2.08B, composta da 15.2% di stipendio e 84.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.05% delle azioni della società, per un valore di MX$ 427.57M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 7.1 anni e 8.4 anni.

Informazioni chiave

Christophe Weber

Amministratore delegato

JP¥2.1b

Compenso totale

Percentuale dello stipendio del CEO	15.2%
Mandato del CEO	10.4yrs
Proprietà del CEO	0.05%
Durata media del management	7.1yrs
Durata media del Consiglio di amministrazione	8.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Christophe Weber rispetto agli utili di Takeda Pharmaceutical?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	JP¥290b
Jun 30 2024	n/a	n/a	JP¥150b
Mar 31 2024	JP¥2b	JP¥317m	JP¥144b
Dec 31 2023	n/a	n/a	JP¥178b
Sep 30 2023	n/a	n/a	JP¥192b
Jun 30 2023	n/a	n/a	JP¥301b
Mar 31 2023	JP¥2b	JP¥295m	JP¥317b
Dec 31 2022	n/a	n/a	JP¥275b
Sep 30 2022	n/a	n/a	JP¥213b
Jun 30 2022	n/a	n/a	JP¥197b
Mar 31 2022	JP¥2b	JP¥281m	JP¥230b
Dec 31 2021	n/a	n/a	JP¥439b
Sep 30 2021	n/a	n/a	JP¥473b
Jun 30 2021	n/a	n/a	JP¥431b
Mar 31 2021	JP¥2b	JP¥267m	JP¥376b
Dec 31 2020	n/a	n/a	JP¥181b
Sep 30 2020	n/a	n/a	JP¥56b
Jun 30 2020	n/a	n/a	JP¥120b
Mar 31 2020	JP¥2b	JP¥273m	JP¥44b
Dec 31 2019	n/a	n/a	JP¥13b
Sep 30 2019	n/a	n/a	JP¥83b
Jun 30 2019	n/a	n/a	JP¥64b
Mar 31 2019	JP¥2b	JP¥269m	JP¥135b
Dec 31 2018	n/a	n/a	JP¥110b
Sep 30 2018	n/a	n/a	JP¥141b
Jun 30 2018	n/a	n/a	JP¥120b
Mar 31 2018	JP¥1b	JP¥254m	JP¥187b

Compensazione vs Mercato: La retribuzione totale di Christophe ($USD 13.45M ) è superiore alla media delle aziende di dimensioni simili nel mercato MX ($USD 5.74M ).

Compensazione vs guadagni: La retribuzione di Christophe è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Christophe Weber (58 yo)

10.4yrs

Mandato

JP¥2,083,000,000

Compensazione

Mr. Christophe Weber has been the President and Chief Executive Officer of Takeda Pharmaceutical Company Limited since June 27, 2014 and April 2015 respectively and served as its Chief Operating Officer fr...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Christophe Weber	President	10.4yrs	JP¥2.08b	0.050% MX$ 427.6m
Seigo Izumo	Chair of Management Board	no data	Nessun dato	Nessun dato
Milano Furuta	CFO & Director	less than a year	Nessun dato	0.00083% MX$ 7.2m
Haruhiko Hirate	Member of Management Board	no data	Nessun dato	Nessun dato
Salvatore Alesci	Member of Management Board and Head of R&D Global Science & Biomedical Policy	no data	Nessun dato	Nessun dato
Norimasa Takeda	Chief Accounting Officer & Corporate Controller	no data	Nessun dato	Nessun dato
Iwaaki Taniguchi	Senior Vice President of Corporate Finance & Controlling Department	11.7yrs	Nessun dato	Nessun dato
Gabriele Ricci	Chief Data & Technology Officer	2.8yrs	Nessun dato	Nessun dato
Christopher David O'Reilly	Global Head of Investor Relations & Global Finance	4.2yrs	Nessun dato	Nessun dato
Yoshihiro Nakagawa	Global General Counsel	10.1yrs	Nessun dato	Nessun dato
Mwana Lugogo	Chief Ethics & Compliance Officer	10.1yrs	Nessun dato	Nessun dato
Lauren Duprey	Chief Human Resources Officer	3.8yrs	Nessun dato	Nessun dato

7.1yrs

Durata media

51.5yo

Età media

Gestione esperta: Il team dirigenziale di TAK N è esperto e expertise (durata media dell'incarico 7.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Christophe Weber	President	10.4yrs	JP¥2.08b	0.050% MX$ 427.6m
Milano Furuta	CFO & Director	no data	Nessun dato	0.00083% MX$ 7.2m
Andrew S. Plump	President of Research & Development and Representative Director	9.4yrs	JP¥972.00m	0.0087% MX$ 75.3m
John M. Maraganore	Independent External Director	2.4yrs	JP¥32.00m	Nessun dato
Steven S. Gillis	Independent External Director	5.8yrs	JP¥44.00m	0.00026% MX$ 2.2m
Emiko Higashi	Independent External Director	8.4yrs	JP¥49.00m	0.00016% MX$ 1.4m
Yoshiaki Fujimori	Independent External Director	8.4yrs	JP¥40.00m	0.00079% MX$ 6.8m
Ian T. Clark	Independent External Director	5.8yrs	JP¥44.00m	0.000070% MX$ 603.7k
Jean-Luc Butel	Independent External Director	5.4yrs	JP¥38.00m	Nessun dato
Michel Orsinger	Independent External Director	8.4yrs	JP¥46.00m	Nessun dato
Masami Iijima	Independent External Chair	3.4yrs	JP¥43.00m	0.000020% MX$ 172.5k
Koji Hatsukawa	Independent External Director	8.4yrs	JP¥43.00m	0.00063% MX$ 5.4m

8.4yrs

Durata media

66.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di TAK N sono considerati esperti (durata media dell'incarico 8.4 anni).

Takeda Pharmaceutical Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda Pharmaceutical Company Limited Announces Board Changes

Recent updates

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Takeda Pharmaceutical Company Limited Proposes Dividend

Takeda Pharmaceutical Company Limited to Report Q2, 2024 Results on Oct 26, 2023

Takeda Announces S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year 2023

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda Pharmaceutical Company Limited Announces FDA Approves the Supplemental Biologics License Application for the Expanded Use of TAKHZYRO

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Takeda Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on May 11, 2023

Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media